Evidence of significant hearing loss during the early days of use of cisplatin as a
chemotherapeutic agent in cancer patients has stimulated research into the causes and …

Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …

Touch submodalities, such as flutter and pressure, are mediated by somatosensory afferents
whose terminal specializations extract tactile features and encode them as action potential …

Because there are currently no biological treatments for hearing loss, we sought to advance
gene therapy approaches to treat genetic deafness. We focused on Usher syndrome, a …

Most genetic diseases arise from recessive point mutations that require correction, rather
than disruption, of the pathogenic allele to benefit patients. Base editing has the potential to …

Gap junctions are essential to the function of multicellular animals, which require a high
degree of coordination between cells. In vertebrates, gap junctions comprise connexins and …

The inner ear contains sensory epithelia that detect head movements, gravity and sound. It
is unclear how to develop these sensory epithelia from pluripotent stem cells, a process that …

The somatosensory system mediates fundamental physiological functions, including the
senses of touch, pain and proprioception. This variety of functions is matched by a diverse …

TRPA1, a member of the transient receptor potential (TRP) family of ion channels, is
expressed by dorsal root ganglion neurons and by cells of the inner ear, where it has …

Genetic hearing loss accounts for up to 50% of prelingual deafness worldwide, yet there are
no biologic treatments currently available. To investigate gene therapy as a potential …